EUCTR2004-001397-92-GB进行中（未招募）1 期
An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha - N/A
ovartis Pharmaceuticals UK Ltd0 个研究点目标入组 532 人开始时间: 2005年2月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 532
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •As for original protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •AS for original protocol
研究者
相似试验
进行中（未招募）
1 期
An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute myeloid leukaemia, and accelerated phase chronic myeloid leukemia - N/AEUCTR2004-001396-19-GBovartis Pharmaceuticals UK Ltd293
进行中（未招募）
不适用
An extension to a phase II study to determine the safety and the anti- leukemic effects of STI571 in adults patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia and accelerate phase myeloid leukemia.EUCTR2005-001381-14-ITOVARTIS FARMA294
进行中（未招募）
1 期
An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alphatreatment of patients with CML who are refractory to or intolerant of interferon alpha.MedDRA version: 14.1Level: LLTClassification code 10052065Term: Chronic phase chronic myeloid leukaemiaSystem Organ Class: 100000004864EUCTR2005-001382-33-ITOVARTIS FARMA532
进行中（未招募）
1 期
A study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy (Extension study to PRO044-CLIN-01)MedDRA version: 17.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne muscular dystrophyEUCTR2013-003605-26-NLProsensa Therapeutics B.V.18
进行中（未招募）
1 期
A study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy (Extension study to PRO044-CLIN-01)MedDRA version: 18.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne muscular dystrophyEUCTR2013-003605-26-BEProsensa Therapeutics B.V.18